Northern Trust Corp increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 2.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 443,163 shares of the biotechnology company’s stock after buying an additional 11,655 shares during the quarter. Northern Trust Corp owned about 1.02% of United Therapeutics worth $50,145,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the stock. WINTON GROUP Ltd acquired a new stake in United Therapeutics during the second quarter worth approximately $3,784,000. Andra AP fonden acquired a new stake in United Therapeutics during the second quarter worth approximately $8,679,000. California Public Employees Retirement System grew its position in United Therapeutics by 8.8% during the second quarter. California Public Employees Retirement System now owns 194,104 shares of the biotechnology company’s stock worth $21,963,000 after buying an additional 15,752 shares in the last quarter. Worldquant Millennium Quantitative Strategies LLC acquired a new stake in United Therapeutics during the second quarter worth approximately $347,000. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp grew its position in United Therapeutics by 18.9% during the second quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 33,400 shares of the biotechnology company’s stock worth $3,779,000 after buying an additional 5,300 shares in the last quarter. 95.83% of the stock is currently owned by institutional investors and hedge funds.
Shares of UTHR stock opened at $123.11 on Friday. The firm has a market capitalization of $5.57 billion, a price-to-earnings ratio of 11.30, a price-to-earnings-growth ratio of 28.86 and a beta of 1.20. United Therapeutics Co. has a fifty-two week low of $100.57 and a fifty-two week high of $152.55. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.35 and a current ratio of 4.64.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.57 by $1.41. The firm had revenue of $444.50 million for the quarter, compared to the consensus estimate of $368.63 million. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The company’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the business posted $4.37 EPS. On average, analysts forecast that United Therapeutics Co. will post 14.77 earnings per share for the current year.
In related news, Director Christopher Causey sold 810 shares of the firm’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $119.00, for a total transaction of $96,390.00. Following the sale, the director now owns 1,555 shares of the company’s stock, valued at approximately $185,045. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Richard Giltner sold 3,240 shares of the firm’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total value of $419,191.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,860 shares of company stock worth $611,161. Company insiders own 8.20% of the company’s stock.
A number of equities research analysts recently issued reports on UTHR shares. Wedbush set a $253.00 price target on United Therapeutics and gave the stock a “buy” rating in a research report on Thursday, September 27th. HC Wainwright set a $95.00 price target on United Therapeutics and gave the stock a “hold” rating in a research report on Monday, August 13th. BidaskClub raised United Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, September 18th. Zacks Investment Research downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Sunday, July 15th. Finally, Standpoint Research raised United Therapeutics from a “hold” rating to a “buy” rating in a report on Friday. Two research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. United Therapeutics currently has an average rating of “Hold” and an average target price of $138.86.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Story: What factors cause inflation to rise?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.